Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 135

1.

Metabolism and disposition of varenicline, a selective alpha4beta2 acetylcholine receptor partial agonist, in vivo and in vitro.

Obach RS, Reed-Hagen AE, Krueger SS, Obach BJ, O'Connell TN, Zandi KS, Miller S, Coe JW.

Drug Metab Dispos. 2006 Jan;34(1):121-30. Epub 2005 Oct 12.

2.

Species differences in the biotransformation of an alpha 4 beta 2 nicotinic acetylcholine receptor partial agonist: the effects of distinct glucuronide metabolites on overall compound disposition.

Shaffer CL, Gunduz M, Ryder TF, O'Connell TN.

Drug Metab Dispos. 2010 Feb;38(2):292-301. doi: 10.1124/dmd.109.030171. Epub 2009 Nov 12.

3.

Biotransformation of an alpha4beta2 nicotinic acetylcholine receptor partial agonist in sprague-dawley rats and the dispositional characterization of its N-carbamoyl glucuronide metabolite.

Shaffer CL, Ryder TF, Venkatakrishnan K, Henne IK, O'Connell TN.

Drug Metab Dispos. 2009 Jul;37(7):1480-9. doi: 10.1124/dmd.109.027037. Epub 2009 Apr 1.

4.

Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation.

Coe JW, Brooks PR, Vetelino MG, Wirtz MC, Arnold EP, Huang J, Sands SB, Davis TI, Lebel LA, Fox CB, Shrikhande A, Heym JH, Schaeffer E, Rollema H, Lu Y, Mansbach RS, Chambers LK, Rovetti CC, Schulz DW, Tingley FD 3rd, O'Neill BT.

J Med Chem. 2005 May 19;48(10):3474-7.

PMID:
15887955
5.

Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors.

Mihalak KB, Carroll FI, Luetje CW.

Mol Pharmacol. 2006 Sep;70(3):801-5. Epub 2006 Jun 9.

6.

The pharmacokinetic and tolerability profile of varenicline in healthy Chinese volunteers.

Xiao Y, Lv Y, Zhang X, Guo Y, Bergstrom T.

Int J Clin Pharmacol Ther. 2009 Apr;47(4):246-54.

PMID:
19356390
7.

Biotransformation of a GABAA receptor partial agonist in sprague-dawley rats and cynomolgus monkeys: identification of two unique N-carbamoyl metabolites.

Shaffer CL, Gunduz M, O'Connell TN, Obach RS, Yee S.

Drug Metab Dispos. 2005 Nov;33(11):1688-99. Epub 2005 Aug 4.

8.

Multiple-dose pharmacokinetics of the selective nicotinic receptor partial agonist, varenicline, in healthy smokers.

Faessel HM, Gibbs MA, Clark DJ, Rohrbacher K, Stolar M, Burstein AH.

J Clin Pharmacol. 2006 Dec;46(12):1439-48.

PMID:
17101743
9.

Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid.

Rollema H, Chambers LK, Coe JW, Glowa J, Hurst RS, Lebel LA, Lu Y, Mansbach RS, Mather RJ, Rovetti CC, Sands SB, Schaeffer E, Schulz DW, Tingley FD 3rd, Williams KE.

Neuropharmacology. 2007 Mar;52(3):985-94. Epub 2006 Dec 8.

PMID:
17157884
10.

Single-dose pharmacokinetics of varenicline, a selective nicotinic receptor partial agonist, in healthy smokers and nonsmokers.

Faessel HM, Smith BJ, Gibbs MA, Gobey JS, Clark DJ, Burstein AH.

J Clin Pharmacol. 2006 Sep;46(9):991-8.

PMID:
16920893
11.

Single- and multiple-dose pharmacokinetics of the selective nicotinic receptor partial agonist, varenicline, in healthy Japanese adult smokers.

Kikkawa H, Maruyama N, Fujimoto Y, Hasunuma T.

J Clin Pharmacol. 2011 Apr;51(4):527-37. doi: 10.1177/0091270010372388. Epub 2010 Jun 15.

PMID:
20551220
12.

Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man.

Walker DK, Ackland MJ, James GC, Muirhead GJ, Rance DJ, Wastall P, Wright PA.

Xenobiotica. 1999 Mar;29(3):297-310.

PMID:
10219969
13.

The high-affinity nAChR partial agonists varenicline and sazetidine-A exhibit reinforcing properties in rats.

Paterson NE, Min W, Hackett A, Lowe D, Hanania T, Caldarone B, Ghavami A.

Prog Neuropsychopharmacol Biol Psychiatry. 2010 Dec 1;34(8):1455-64. doi: 10.1016/j.pnpbp.2010.07.037. Epub 2010 Aug 11.

PMID:
20708056
14.

Varenicline: progress in smoking cessation treatment.

Glover ED, Rath JM.

Expert Opin Pharmacother. 2007 Aug;8(11):1757-67. Review.

PMID:
17685891
15.

Varenicline: a first-line treatment option for smoking cessation.

Garrison GD, Dugan SE.

Clin Ther. 2009 Mar;31(3):463-91. doi: 10.1016/j.clinthera.2009.03.021. Review.

PMID:
19393839
16.

Varenicline for smoking cessation.

Tonstad S.

Expert Rev Neurother. 2007 Feb;7(2):121-7. Review.

PMID:
17286546
17.
18.

Pharmacokinetics, safety, and tolerability after single and multiple oral doses of varenicline in elderly smokers.

Burstein AH, Fullerton T, Clark DJ, Faessel HM.

J Clin Pharmacol. 2006 Nov;46(11):1234-40.

PMID:
17050788
19.
20.

Metabolism and excretion of RWJ-333369 [1,2-ethanediol, 1-(2-chlorophenyl)-, 2-carbamate, (S)-] in mice, rats, rabbits, and dogs.

Mamidi RN, Mannens G, Annaert P, Hendrickx J, Goris I, Bockx M, Janssen CG, Kao M, Kelley MF, Meuldermans W.

Drug Metab Dispos. 2007 Apr;35(4):566-75. Epub 2007 Jan 12.

Supplemental Content

Support Center